Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$40 Mln
P/E Ratio
--
P/B Ratio
0.54
Industry P/E
--
Debt to Equity
0.15
ROE
-0.76 %
ROCE
-56.94 %
Div. Yield
0 %
Book Value
1.67
EPS
-1.6
CFO
$-144.25 Mln
EBITDA
$-175.36 Mln
Net Profit
$-164.63 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Werewolf Therapeutics (HOWL)
| -42.93 | -21.07 | -37.44 | -87.49 | -40.65 | -- | -- |
|
BSE Sensex*
| 2.74 | 3.84 | 5.91 | 9.03 | 11.80 | 20.14 | 11.37 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Werewolf Therapeutics (HOWL)
| -61.36 | 88.29 | -82.79 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.44 | 10,315.11 | 21.27 | 23.13 | |
| 298.18 | 8,705.27 | 22.77 | 66.44 | |
| 27.46 | 10,589.59 | -- | -28.77 | |
| 106.46 | 10,559.67 | 32.44 | 14.16 |
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company designs conditionally activated molecules that stimulate... adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. The company's lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. Read more
Founder, CEO, President, Secretary & Director
Dr. Daniel J. Hicklin Ph.D.
Founder, CEO, President, Secretary & Director
Dr. Daniel J. Hicklin Ph.D.
Headquarters
Watertown, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Werewolf Therapeutics Inc (HOWL) stood at $ 127 Mln as on 31-Dec-24
The share price of Werewolf Therapeutics Inc (HOWL) is $0.84 (NASDAQ) as of 28-Apr-2025 16:15 EDT. Werewolf Therapeutics Inc (HOWL) has given a return of -40.65% in the last 3 years.
Werewolf Therapeutics Inc (HOWL) has a market capitalisation of $ 40 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Werewolf Therapeutics Inc (HOWL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Werewolf Therapeutics Inc (HOWL) and enter the required number of quantities and click on buy to purchase the shares of Werewolf Therapeutics Inc (HOWL).
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. The company's lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
The CEO & director of Dr. Daniel J. Hicklin Ph.D.. is Werewolf Therapeutics Inc (HOWL), and CFO & Sr. VP is Dr. Daniel J. Hicklin Ph.D..
There is no promoter pledging in Werewolf Therapeutics Inc (HOWL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Werewolf Therapeutics Inc. (HOWL) | Ratios |
|---|---|
|
Return on equity(%)
|
-76.33
|
|
Operating margin(%)
|
-3493.85
|
|
Net Margin(%)
|
-3740.85
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Werewolf Therapeutics Inc (HOWL) was $0 Mln.
$-0.05
(
